We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Kymera Therapeutics, Inc. (KYMR - Free Report) shares soared 10% in the last trading session to close at $99.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.6% gain over the past four weeks.
Kymera’s sharp stock price gain appears to reflect growing investor confidence in the broad potential of the company’s pipeline candidates. Its lead candidate, KT-621, is a first-in-class, once-daily oral STAT6 degrader being developed for type II inflammatory diseases, including atopic dermatitis (AD) and asthma. The candidate is currently in phase II studies for AD and eosinophilic asthma, with data expected in 2027. Beyond STAT6, Kymera’s clinical pipeline comprises two other early-stage candidates being developed for autoimmune and chronic immuno-inflammatory diseases.
This company is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of +32.6%. Revenues are expected to be $42.86 million, up 273.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Kymera Therapeutics, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.
Kymera Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Insmed (INSM - Free Report) , finished the last trading session 2.9% higher at $98.61. INSM has returned -9.8% over the past month.
For Insmed, the consensus EPS estimate for the upcoming report has changed +1% over the past month to -$0.75. This represents a change of +55.9% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics, Inc. (KYMR - Free Report) shares soared 10% in the last trading session to close at $99.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.6% gain over the past four weeks.
Kymera’s sharp stock price gain appears to reflect growing investor confidence in the broad potential of the company’s pipeline candidates. Its lead candidate, KT-621, is a first-in-class, once-daily oral STAT6 degrader being developed for type II inflammatory diseases, including atopic dermatitis (AD) and asthma. The candidate is currently in phase II studies for AD and eosinophilic asthma, with data expected in 2027. Beyond STAT6, Kymera’s clinical pipeline comprises two other early-stage candidates being developed for autoimmune and chronic immuno-inflammatory diseases.
This company is expected to post quarterly loss of $0.64 per share in its upcoming report, which represents a year-over-year change of +32.6%. Revenues are expected to be $42.86 million, up 273.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Kymera Therapeutics, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Kymera Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Insmed (INSM - Free Report) , finished the last trading session 2.9% higher at $98.61. INSM has returned -9.8% over the past month.
For Insmed, the consensus EPS estimate for the upcoming report has changed +1% over the past month to -$0.75. This represents a change of +55.9% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).